Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||MK-1454 + Pembrolizumab||Phase I||Actionable||In a Phase I trial, MK-1454 in combination with Keytruda (pembrolizumab) resulted in partial response in 24% (6/25) and a disease control rate of 48% (12/25) in patients with advanced solid tumors (Ann Oncol, Oct 2018, 29 (suppl 8), abstract LBA15; NCT03010176).||detail...|
|PubMed Id||Reference Title||Details|
|Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas||Full reference...|